Can-Fite BioPharma Ltd. (CANF)
1.49
-0.03 (-1.97%)
At close: Apr 03, 2025, 3:59 PM
1.49
-0.11%
After-hours: Apr 03, 2025, 08:00 PM EDT
-1.97% (1D)
| Bid | 1.32 |
| Market Cap | 9.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.6 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | -2.14 |
| Analyst | Buy |
| Ask | 1.52 |
| Volume | 54,079 |
| Avg. Volume (20D) | 190,635 |
| Open | 1.49 |
| Previous Close | 1.52 |
| Day's Range | 1.45 - 1.50 |
| 52-Week Range | 1.29 - 4.69 |
| Beta | 0.46 |
About CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2012
Employees 8
Stock Exchange AMEX
Ticker Symbol CANF
Website https://www.canfite.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CANF stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 571.14% from the latest price.
Stock Forecasts2 weeks ago
-19.31%
Can-Fite Biopharma shares are trading lower. The c...
Unlock content with
Pro Subscription
2 weeks ago
+22.42%
Can-Fite Biopharma shares are trading higher after the company received FDA approval for compassionate use of its namodenoson for pancreatic cancer.
